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ABSTRACT
Anti-epidermal growth factor receptor (EGFR) antibody therapy is used in 
EGFR expressing cancers including lung, colon, head and neck, and bladder cancers, 
however results have been modest. Near infrared photoimmunotherapy (NIR-PIT) is a 
highly selective tumor treatment that employs an antibody-photo-absorber conjugate 
which is activated by NIR light. NIR-PIT is in clinical trials in patients with recurrent 
head and neck cancers using cetuximab-IR700 as the conjugate. However, its use 
has otherwise been restricted to mouse models. This is an effort to explore larger 
animal models with NIR-PIT. We describe the use of a recombinant canine anti-EGFR 
monoclonal antibody (mAb), can225IgG, conjugated to the photo-absorber, IR700DX, 
in three EGFR expressing canine transitional cell carcinoma (TCC) cell lines as a 
prelude to possible canine clinical studies. Can225-IR700 conjugate showed specific 
binding and cell-specific killing after NIR-PIT on EGFR expressing cells in vitro. In the 
in vivo study, can225-IR700 conjugate demonstrated accumulation of the fluorescent 
conjugate with high tumor-to-background ratio. Tumor-bearing mice were separated 
into 4 groups: (1) no treatment; (2) 100 µg of can225-IR700 i.v. only; (3) NIR light 
exposure only; (4) 100 µg of can225-IR700 i.v., NIR light exposure. Tumor growth 
was significantly inhibited by NIR-PIT treatment compared with the other groups  
(p < 0.001), and significantly prolonged survival was achieved (p < 0.001 vs. 
other groups) in the treatment groups. In conclusion, NIR-PIT with can225-IR700 
is a promising treatment for canine EGFR-expressing cancers, including invasive 
transitional cell carcinoma in pet dogs, that could provide a pathway to translation 
to humans. 
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INTRODUCTION
Near infrared photoimmunotherapy (NIR-PIT) 
is a newly developed cancer treatment that employs a 
highly targeted mAb-photo-absorber conjugate (APC). 
The photo-absorber, IRDye700DX (IR700, silica-
phthalocyanine dye), is a highly hydrophilic dye, 
differentiating it from prior hydrophobic dyes used in 
photodynamic therapy (PDT) [1]. A first-in-human trial 
of epidermal growth factor receptor (EGFR) targeted 
NIR-PIT in patients with inoperable head and neck cancer 
was initiated in June 2015 (https://clinicaltrials.gov/
ct2/show/NCT02422979) and has recently completed 
Phase 2 testing. In this trial, patients were injected with 
cextuximab-IR700 conjugate, (referred to as RM1929 
in the study), that binds EGFR on the cell membrane of 
head and neck cancers. About 24 hours later the tumor is 
exposed to NIR light by means of a laser at a wavelength 
of 690 nm which is absorbed by IR700. NIR-PIT using 
cetuximab-IR700 conjugate (RM1929) could be applied to 
other EGFR-expressing cancers in the body such as lung, 
colon, breast, esophagus, and bladder cancers.
In the United States (US), bladder cancer is the 
fourth most common cancer, with 79,000 estimated new 
cases and 17,000 bladder cancer related deaths in 2017 
[2] and related to renally secreted toxins for instance from 
cigarette smoking [3]. At the time of diagnosis, most 
patients present with non-invasive bladder cancer, which 
has a 50% to 70% rate of superficial recurrence and a 10% 
to 30% rate of progression to invasive bladder cancer 
[4, 5]. Invasive bladder cancer outcomes remain poor 
despite aggressive multimodal treatment, with less than 
10% survival at 5 years [6]. Further, bladder cancer is a 
disease of the elderly with coexistent medical conditions, 
and consequently approximately 50% of patients will 
be ineligible for cisplatin-based chemotherapy [7]. New 
highly targeted cancer therapies with improved side effect 
profiles for targeting invasive bladder cancer are urgently 
needed.
Studies in relevant animal models are essential to 
improve the management of invasive bladder cancer 
in human. Several experimentally induced models of 
transitional cell carcinoma (TCC; also referred to as 
invasive urothelial carcinoma) have been established, 
including chemically induced tumors, transgenic mouse 
models, and orthotopic xenograft models [8–10]. Although 
these experimental animal models are of great value and 
are constantly in use for invasive bladder cancer research, 
there is a need for complementary larger animal models 
in which the disease is naturally occurring, invades and 
metastasizes consistently, and more closely mimics the 
human condition. This will permit the development of 
instrumentation suitable for translation to humans and will 
improve the understanding of treatment effects. Dogs with 
naturally occurring invasive TCC provide an ideal animal 
model to address this need [11–13].
There are approximately 70 million pet dogs in the 
US, and it is estimated that 20 to 30,000 of these dogs 
develop bladder cancer each year [14]. In household 
dogs, topical insecticides and obesity seem to be more 
important than second hand smoke [15]. Naturally 
occurring bladder cancer in dogs very closely mimics 
human invasive bladder cancer, specifically high-grade 
invasive TCC in regard to histological appearance, cellular 
and molecular features, biological behavior including 
metastasis, and response to chemotherapy [11, 14]. In 
addition, molecular markers that have been implicated 
to be of importance in human invasive TCC, have also 
played a similar role in dogs [12, 13]. Thus, pet dogs offer 
a unique naturally occurring model of invasive bladder 
cancer, where response to new cancer therapies can be 
assessed and promising results translated into humans. 
In addition, the compressed life span of dogs makes the 
study of bladder cancer feasible from its earliest stages to 
death of the host in a timely manner, and the intact host 
immunity of the tumor-bearing pet dog allows assessment 
of immunomodulatory therapies from both efficacy and 
toxicity standpoints.
NIR-PIT has been shown to be effective with a 
variety of different antibodies, but has not been previously 
tested with a canine antibody and canine cancer models 
[16–21]. The purpose of this work was to establish NIR-
PIT for canine invasive TCC in vitro and in vivo using 
the canine antibody can225IgG, which was constructed 
based on the exact EGFR-specific antigen-binding site of 
cetuximab [22] for comparative trials [23], and showed 
comparable affinity to the canine EGFR, which is 95% 
homologous to human EGFR [24]. Using three EGFR-
expressing invasive canine TCC cell lines, K9TCC original 
(TCC original; minimal EGFR expression), K9TCC-PU 
AxA (TCC AXA; low EGFR expression) and K9TCC-PU 
Sh (TCC SH; intermediate EGFR expression), in vitro 
binding and in vitro NIR-PIT effects were evaluated. After 
in vivo tumor accumulation and intratumoral distribution 
were evaluated, NIR-PIT was then performed in a tumor-
bearing mouse model in vivo. These experiments serve 
as a basis and provide rationale for moving forward into 
an actual clinical trial in privately-owned pet dogs with 
spontaneous cancers.
RESULTS
In vitro characterization of three TCC cell lines
As defined by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE), can225-IR700 and 
non-conjugated control can225IgG showed an identical 
molecular weight, around 150 kDa, and fluorescence 
intensity was confirmed in the band of can225-IR700 
(Figure 1A). After a 6 h incubation with can225-IR700, 
TCC SH cells demonstrated high fluorescence signal, which 
was confirmed with flow cytometry (Figure 1B). TCC AXA 
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cells also showed intermediate fluorescence signal (Figure 
1B). On the other hand, TCC original cells showed only 
slight fluorescence signal. Fluorescence signal in all three 
TCC cell lines was completely blocked by adding excess 
can225IgG (Figure 1B), confirming that can225-IR700 
specifically binds to EGFR on the cells.
In vitro NIR-PIT
Based on Propidium iodide (PI) incorporation, 
minimal NIR-PIT effects were observed in TCC original 
cells when 32 J/cm² of NIR light was applied (Figure 1C). 
On the other hand, percentage of cell death increased in 
a light dose dependent manner in both TCC AXA (Figure 
1D) and TCC SH cells (Figure 1E). Over 60% of TCC SH 
cells died when exposed to 16 J/cm² of NIR light. There 
was no significant cytotoxicity associated with NIR light 
exposure alone in the absence of can225-IR700 or with 
can225-IR700 alone without NIR light exposure. 
In fluorescence microscopic studies, slight 
fluorescence signal was shown in TCC original cell, 
however, there was no cytotoxicity upon excitation with 
NIR light in TCC original cell (Figure 2A). On the other 
hand, NIR light exposure induced cellular swelling, bleb 
formation, and rupture of vesicles consistent with necrotic 
cell death in TCC AXA and TCC SH cells. Most of these 
morphologic changes were observed within 15 min of 
NIR light exposure (Figure 2B and 2C), indicating rapid 
induction of necrotic cell death. From these in vitro results, 
we selected TCC SH cells for in vivo study.
Figure 1: Confirmation of EGFR expression as a target for NIR-PIT in three TCC cell lines, and evaluation of in vitro 
NIR-PIT. (A) Validation of can225-IR700 by SDS-PAGE (left: Colloidal Blue staining, right: fluorescence). Diluted can225IgG was used 
as a control. (B) Expressions of EGFR in three TCC cell lines were evaluated by flow cytometry. After 6 h of can225-IR700 incubation, 
TCC SH cells showed high fluorescence signal, TCC AXA cells showed intermediate fluorescence signal, and TCC original cells showed 
low fluorescence signal. Fluorescence in three TCC cell lines was completely blocked by adding excess can225IgG. (C) Membrane 
damage of TCC original cells induced by NIR light exposure was measured with the dead cell count using propidium iodide (PI) staining. 
No membrane damage was observed in TCC original cells after 0.25–16 J/cm2 of NIR light exposure. Membrane damage was only shown 
after 32 J/cm2 of NIR light exposure (n = 5, **p < 0.01, vs. untreated control, by Student’s t test). (D) Membrane damage of TCC AXA 
cells induced by NIR-PIT was measured with the dead cell count using PI staining, which increased in a light dose dependent manner (n = 
5, **p < 0.01, vs. untreated control, by Student’s t test). There was no significant cytotoxicity associated with NIR light exposure alone in 
the absence of can225-IR700 and with can225-IR700 alone without NIR light exposure. (E) Membrane damage of TCC SH cells induced 
by NIR-PIT was measured with the dead cell count using PI staining, which increased in a light dose dependent manner (n = 5, **p < 0.01, 
vs. untreated control, by Student’s t test). The NIR-PIT effects in TCC SH cells were higher than TCC original and TCC AXA cells. There 
was no significant cytotoxicity associated with NIR light exposure alone in the absence of can225-IR700 and with can225-IR700 alone 
without NIR light exposure.
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In vivo fluorescence imaging studies
The fluorescence intensity of can225-IR700 in 
TCC SH tumor was high within 1 day after can225-
IR700 injection but decreased over the following days 
(Figure 3A and 3B). The fluorescence signal in the 
liver was high for the first 9 hours after APC injection 
but then decreased (Figure 3A and 3B). On the other 
hand, the TBR of can225-IR700 in tumor and liver was 
high within 1 day after APC injection, following which 
the TBR did not change clearly for several days, then 
decreased gradually (Figure 3C). TBR of can225-IR700 
was high in tumor due to specific APC binding to EGFR 
expressing TCC SH cells, while TBR was high in liver 
likely due to non-specific accumulation of can225-IR700 
conjugate as the liver is not known to express EGFR. 
To obtain the maximal therapeutic effect, fluorescence 
caused by binding of the APC should be high in tumor 
and low in background. Fluorescence of TCC SH tumor 
was high after APC injection, while fluorescence signal of 
Figure 2: In vitro fluorescence microscopic images of three TCC cell lines. (A) Differential interference contrast (DIC) and 
fluorescence images of TCC original cells after incubation with can225-IR700 for 6 h. Slight fluorescence signal was shown in TCC original 
cell. There was no cytotoxicity upon excitation with low dose NIR light (after 15 min) in TCC original cell. White scale bars = 20 µm. 
(B) DIC and fluorescence images of TCC AXA cells after incubation with can225-IR700 for 6 h. Intermediate fluorescence signal was 
shown in TCC AXA cell. Necrotic cell death was observed upon excitation with low dose NIR light (after 15 min) in TCC AXA cell. 
(C) DIC and fluorescence images of TCC SH cells after incubation with can225-IR700 for 6 h. High fluorescence signal was shown in TCC 
SH cell. Necrotic cell death was observed upon excitation with low dose of NIR light (after 15 min) in TCC SH cell.
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background, including liver, decreased beginning 9 hours 
after APC injection. Thus, we used 1 day of incubation 
with APC to get the maximal difference between tumor 
and background normal tissue.
Histological analysis
The treatment and imaging regimen is shown 
in Figure 4A. High fluorescence intensity was shown 
in resected tumors 24 h post can225-IR700 injection, 
compared with that in control and NIR light only tumors. 
The majority of fluorescence signal in tumors disappeared 
24 h after NIR-PIT in resected tumors (Figure 4B). In 
frozen histologic specimens, high fluorescence intensity 
was also shown in tumors 24 h after can225-IR700 
injection, and the signal decreased 24 h after NIR-PIT 
(Figure 4C). There were no fluorescence signals in the 
tumors without can225-IR700 injection (control tumor 
and NIR light only tumor) (Figure 4C). Hematoxylin and 
eosin (H&E) staining of NIR-PIT treated TCC SH tumors 
revealed diffuse necrosis and micro-hemorrhage, with 
scattered clusters of live but damaged tumor cells, while 
no obvious damage was observed in the control tumors, 
tumors receiving only can225-IR700 but no light, and the 
tumors exposed to NIR light only, without can225-IR700 
injection (Figure 4D).
In vivo NIR-PIT
The treatment and imaging regimen is shown in 
Figure 5A. One day after injection of can225-IR700, 
the tumors showed higher fluorescence intensity than 
did the tumors with no can225-IR700 (Figure 5B). After 
exposure to 50 J/cm2 of NIR light, IR700 fluorescence 
signal of the tumors decreased due to dying cells and 
partial photo-bleaching, while the IR700 fluorescence 
Figure 3: In vivo fluorescence imaging of TCC SH tumor. (A) In vivo can225-IR700 fluorescence real-time imaging of tumor-
bearing mice of TCC SH (right dorsum). The tumor showed high fluorescence intensity after injection and the intensity was gradually 
decreased over days. Most of the excess agent was excreted to the urine immediately after injection. (B) Time course of NIR fluorescence 
signal of IR700 in tumors and livers (n = 10). The IR700 fluorescence intensity of tumor showed high intensities within 1 day after 
can225-IR700 injection but this decreased gradually over days. The IR700 fluorescence intensity of liver showed high within 9 hours after 
APC injection, then this decreased. (C) Time course of NIR fluorescence signal of target-to-background ratio (TBR) in tumors and livers 
(n = 10). TBR of both tumor and liver showed high within three days after can225-IR700 injection, then the TBR was gradually decreased 
over the following days.
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gradually decreased over the following days in tumors 
receiving can225-IR700 without NIR light exposure 
(Figure 5B). Tumor growth was significantly inhibited 
in the NIR-PIT treatment group compared with the three 
control groups (p < 0.001) (Figure 5C), and significantly 
prolonged survival was achieved in the NIR-PIT group 
(p < 0.001 vs other three control groups) (Figure 5D). No 
significant therapeutic effect was observed in the control 
groups, including those receiving can225-IR700 i.v. only 
or in mice exposed to NIR light only. There was no skin 
necrosis or toxicity attributable to can225-IR700 in any 
group.
DISCUSSION
EGFR protein overexpression in TCC/bladder 
cancer has been linked to TCC grade, stage, and survival 
outcomes [25–29]. Thus, EGFR is an important target for 
antibody therapies of invasive bladder cancer in humans 
[30]. However, randomized clinical trial using dual 
inhibitors of EGFR and human epidermal growth factor 
receptor 2 (HER2), lapatinib, failed to improve outcomes 
in invasive bladder cancer patients [31]. Moreover, it was 
reported that the addition of lapatinib to chemotherapy as 
part of neoadjuvant therapy for invasive bladder cancer 
was limited by excessive treatment-related toxicity [32]. 
Therefore, to improve the outcome of invasive bladder 
cancer, treatments with fewer side effects are urgently 
needed.
NIR-PIT has shown excellent selectivity for antigen 
expressing tumor cells with minimal off-target effects. As 
shown in this study, the conjugate can225-IR700 proved 
to be an effective agent for treating an EGFR-expressing 
canine invasive bladder cancer cell line with NIR-PIT. 
NIR-PIT with can225-IR700 led to rapid cell death in vitro 
and tumor growth reduction and survival improvement 
in vivo. Thus, a caninized version of cetuximab-IR700, 
can225IgG [22], could be an effective platform for 
NIR-PIT in EGFR expressing canine invasive bladder 
cancer. Compared with other therapies, antibody-based 
phototherapy has several advantages over conventional 
approaches. For instance, it is minimally invasive and can 
be applied repeatedly [33]. It appears to induce a strong 
immune response that appears to be limited to the treated 
tumor volume, and minimal side effects have been seen in 
early-phase clinical trials. Thus, the ability of can225IgG-
Figure 4: In vivo histological fluorescence distribution, and histological NIR-PIT effect. (A) The regimen of NIR-PIT. 
(B) Fluorescence images of resected TCC SH tumors. White light images (upper) and IR700 fluorescence image (lower). High fluorescence 
intensity was shown in TCC SH tumor 24 h after injection of can225-IR700, but the fluorescence decreased 24 h after NIR-PIT. No IR700 
fluorescence signal was observed in control tumor and NIR light only tumor. (C) DIC and fluorescence microscopy images of TCC SH 
tumor xenografts. High fluorescence intensity was shown in TCC SH tumor 24 h after injection of can225-IR700, but the fluorescence 
decreased 24 h after NIR-PIT. There were no IR700 fluorescence signals in the tumors without can225-IR700 injection (control tumor and 
NIR light only tumor). White scale bars = 100 µm. (D) Resected tumor stained with hematoxylin and eosin (H&E). A few scattered clusters 
of damaged tumor cells were seen within a background of diffuse cellular necrosis and micro-hemorrhage after NIR-PIT, while no obvious 
damage was observed in the control groups, including those receiving can225-IR700 i.v. only (APC i.v. only) or in mice receiving NIR 
light exposure only (NIR light only). Yellow scale bars = 100 µm. Black scale bars = 20 µm.
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IR700 to act as a NIR-PIT agent opens up the possibility 
of testing in immune-competent tumor-bearing dogs.
It is important to differentiate NIR-PIT from 
photodynamic therapy (PDT) that has been used 
for several decades. The photosensitizers used in 
PDT are very hydrophobic and therefore, difficult to 
target. For instance, when antibodies were conjugated 
to PDT photosensitizers, these conjugates were 
immediately recognized by the reticuloendothelial 
system and accumulated in the liver, resulting in 
minimal accumulation in target tumors when applied 
intravenously. In contrast, NIR-PIT employs a water-
soluble silica-phthalocyanine dye, which is conjugated 
to an antibody to form an APC with a biodistribution 
similar to non-conjugated parental antibodies in the body. 
Therefore, once injected intravenously, the APC gradually 
distributes into tumors within days, resulting in sufficient 
accumulation within cancer cells to kill the cells after 
NIR light exposure. Our previous study has shown NIR-
PIT to be highly cell-specific, therefore, non-target cells 
immediately adjacent to targeted cells show minimal toxic 
effect [1].
Based on fluorescence TBR, the can225-IR700 
conjugate achieved sufficient accumulation for NIR-PIT 
(Figure 3). Our results confirm that can225IgG bound to 
canine EGFR on cells specifically and was internalized 
within 6 hours of incubation in EGFR expressing cancer 
cells (Figure 2). Of course, for the treatment of bladder 
cancer, for instance, it is also necessary to modify existing 
cystoscopic equipment to deliver light to the bladder. The 
dog model patient also permits a more realistic appraisal 
of both efficacy and side effects than is possible in mouse 
model, wherein standardized metrics, adopted from 
human clinical trials, are applied for assessment of tumor 
response and attribution and grading of systemic adverse 
events [34, 35].
An important aspect of NIR-PIT is its immunogenic 
nature. Cells treated with NIR-PIT undergo rapid volume 
expansion leading to rupture of the cell membrane and 
extrusion of cell contents into the extracellular space 
[17]. This causes an immunogenic cell death rather than 
apoptotic cell death which is induced by most other 
cancer therapies [36, 37]. After NIR-PIT dying cells 
release neoantigens and signaling moieties including 
Figure 5: In vivo effect of NIR-PIT for TCC SH tumor. (A) NIR-PIT regimen. Fluorescence images were obtained at each time 
point as indicated. (B) In vivo fluorescence real-time imaging of tumor-bearing mice in response to NIR-PIT. One day after injection of 
can225-IR700, the tumors showed higher fluorescence intensity than did the tumor without can225-IR700 (control and NIR light only 
group). The tumor treated by NIR-PIT showed decreasing IR700 fluorescence immediately after NIR-PIT. On the other hand, the IR700 
fluorescence signal gradually decreased over the following days in tumors receiving can225-IR700 i.v. but not NIR light exposure (APC 
i.v. only). (C) Tumor growth was significantly inhibited in the NIR-PIT treatment group with can225-IR700 (n ≧ 10, **p < 0.001 vs other 
three groups, Tukey’s test with ANOVA). (D) Significantly prolonged survival was observed in the NIR-PIT treatment group (n ≧ 10, **p 
< 0.001 vs other three groups, by Log-rank test).
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calreticulin, ATP, and HMGB1 that effectively promote 
maturation of immature dendritic cells [17]. These 
matured dendritic cells are capable not only of digesting 
the cancer cell debris but also present cancer-specific 
antigens to T-effector cells [17]. It is anticipated that 
immunogenic cell death will augment the therapeutic 
effect of NIR-PIT as it selectively kills target cells while 
non-target cells immediately adjacent, including effector 
immune cells, show no toxic effects [1]. Therefore, NIR-
PIT could effectively enforce host tumor immunity. 
Pet dogs trials of NIR-PIT for naturally occurring 
invasive bladder cancer are appropriate to clarify the 
immunological response after NIR-PIT prior to human 
clinical trial of bladder cancer.
This study has several limitations. We performed 
one injection of the can225-IR700 with two exposures of 
NIR light in order to perform a proof-of-principle study 
for demonstrating that NIR-PIT with can225-IR700 was 
effective to treat EGFR-expressing canine cancer models. 
Clearly, repeated dosing of the APC with repeated NIR 
light exposure could have improved the therapeutic effect 
[21, 38]. It would be desirable to extend these studies 
to multiple doses of the APC and NIR light. This study 
was also done in xenograft model of nude mice. In mice, 
NIR light could be delivered into deep tumor, such as 
bladder cancer, using surface illumination, while this is 
impossible in dogs and humans. To deliver NIR light, 
direct exposure of NIR light would be necessary using 
either direct illumination during surgery or using fibro-
optic diffusers via cystoscopes or inserted needles. Finally, 
the current xenograft model does not sufficiently represent 
clinical cancers. Surgically-implanted orthotopic tumor 
models are superior to xenografted tumor models [39–42], 
yet consistently producing orthotopic implants with 
mouse surgery requires highly trained skills. Therefore, 
in this proof-of-principle study of NIR-PIT targeting 
canine bladder cancer, we chose this simple subcutaneous 
xenograft tumor model.
CONCLUSIONS
IR700 conjugate with the caninized version of 
cetuximab, can225IgG, accumulated in high EGFR-
expressing canine invasive transitional bladder cancer 
cells. Subsequent NIR-PIT using can225-IR700 induced 
remarkable therapeutic responses after only a single 
injection of the conjugate and two NIR light exposures in 
an EGFR-expressing canine xenograft tumor model. Thus, 
NIR-PIT utilizing EGFR as the targeting antigen for the 
can225-IR700 shows promise as a new treatment modality 
for naturally-occurring canine invasive TCC in pet dogs as 
a prelude to translation into humans.
MATERIALS AND METHODS
Reagents
Water soluble, silica-phthalocyanine derivative, 
IRDye 700DX NHS ester was obtained from LI-COR 
Biosciences (Lincoln, NE, USA). A caninized version of 
human anti-EGFR antibody (cetuximab), can225IgG, was 
engineered and produced as previously described [22]. All 
other chemicals were of reagent grade.
Can225IgG expression and purification
Can225IgG was expressed as previously described 
[22]. In short, vectors containing the EGFR-specific γ-C 
heavy and κ-light chain sequences were co-transfected 
into CHO-DUKX-B11 cells and expressed under serum-
free conditions in ProCHO 5 medium (Lonza, Basel, 
Switzerland) supplemented with 4 mM L-glutamine. 
Subsequently, can225IgG was affinity-purified from cell 
culture supernatant with a HiTrap Protein G HP column 
(GE Healthcare, Piscataway, NJ, USA) using an ÄKTA 
explorer FPLC system (GE Healthcare, Piscataway, NJ, 
USA).
Synthesis of IR700-conjugated can225
Conjugation of dyes with mAb was performed 
according to a previous report [1]. In brief, can225IgG 
(1.0 mg, 6.8 nmol) was incubated with IR700 NHS 
ester (66.0 μg, 33.8 nmol) in 0.1 M Na2HPO4 (pH 8.6) 
at room temperature for 1 h. The mixture was purified 
with a Sephadex G25 column (PD-10; GE Healthcare, 
Piscataway, NJ, USA). The protein concentration was 
determined with Coomassie Plus protein assay kit 
(Thermo Fisher Scientific Inc, Rockford, IL, USA) by 
measuring the absorption at 595 nm with UV-Vis (8453 
Value System; Agilent Technologies, Santa Clara, CA, 
USA). The concentration of IR700 was measured by 
absorption at 689 nm to confirm the number of fluorophore 
molecules per mAb. The synthesis was controlled so that 
an average of two IR700 molecules was bound to a single 
antibody. We abbreviate IR700 conjugated to can225IgG 
as can225-IR700. As a quality control for the conjugate, 
we performed SDS-PAGE. Conjugate was separated 
by SDS-PAGE with a 4–20% gradient polyacrylamide 
gel (Life Technologies, Gaithersburg, MD, USA). 
A standard marker (Crystalgen Inc., Commack, NY, USA) 
was used as a protein molecular weight marker. After 
electrophoresis at 80 V for 2.5 h, the gel was imaged with 
a Pearl Imager (LI-COR Biosciences, Lincoln, Nebraska, 
USA) using a 700 nm fluorescence channel. We used 
diluted can225IgG as a control. The gel was stained with 
Colloidal Blue staining to determine the molecular weight 
of conjugate.
Oncotarget19034www.oncotarget.com
Cell culture
Three canine transitional bladder cancer cell lines, 
K9TCC original (minimal EGFR expression), K9TCC-
PU AxA (low EGFR expression) and K9TCC-PU Sh 
(intermediate EGFR expression) were kindly provided 
by Dr. Deborah W. Knapp (Purdue University Center for 
Cancer Research, Purdue University, West Lafayette, IN, 
US). All cell lines were established from tumor samples 
of dogs with invasive transitional cell carcinoma (TCC). 
We abbreviate these cell lines as TCC original, TCC AXA, 
and TCC SH. Cells were grown in DMEM/F12 (Life 
Technologies, Gaithersburg, MD, USA) supplemented 
with 10% fetal bovine serum (Life Technologies) in tissue 
culture flasks in a humidified incubator at 37° C in an 
atmosphere of 95% air and 5% carbon dioxide.
Flow cytometry
To verify in vitro can225-IR700 binding, 
fluorescence from cells after incubation with can225-
IR700 was measured using a flow cytometer (FACS 
Calibur, BD BioSciences, San Jose, CA, USA) and 
CellQuest software (BD BioSciences). TCC original, TCC 
AXA and TCC SH cells (2 × 105) were seeded into 12 well 
plates and incubated for 24 h. Cell media was replaced 
with fresh culture media containing 3 µg/mL of can225-
IR700 and incubated for 6 h at 37° C. After washing with 
phosphate buffered saline (PBS), PBS was added. A 488-
nm argon ion laser was used for excitation. Signals from 
cells were collected with a 653-669 nm band-pass filter. To 
validate the specific binding of the conjugated antibody, 
excess naked antibody (30 µg) was used to block can225-
IR700 uptake.
Fluorescence microscopy
To detect the antigen specific localization and effect 
of NIR-PIT, fluorescence microscopy was performed 
(BX61; Olympus America, Inc., Melville, NY, USA). Ten 
thousand TCC original, TCC AXA and TCC SH cells were 
seeded on cover-glass-bottomed dishes and incubated 
for 24 h. Can225-IR700 was then added to the culture 
medium at 3 µg/mL and incubated for 6 h at 37° C. After 
incubation, the cells were washed with PBS. The filter 
set to detect IR700 consisted of a 590–650 nm excitation 
filter, a 665–740 nm band pass emission filter. Transmitted 
light differential interference contrast (DIC) images were 
also acquired.
In vitro NIR-PIT
The cytotoxic effects of NIR-PIT with can225-
IR700 were determined by flow cytometric propidium 
iodide (PI) (Life Technologies) staining, which can detect 
compromised cell membranes. Two hundred thousand 
TCC original, TCC AXA and TCC SH cells were seeded 
into 12 well plates and incubated for 24 h. Medium was 
replaced with fresh culture medium containing 3 µg/ml 
of can225-IR700 and incubated for 6 h at 37° C. After 
washing with PBS, PBS was added, and cells were 
irradiated with a red light-emitting diode (LED), which 
emits light at 690 ± 20 nm wavelength (L690-66-60; 
Marubeni America Co., Santa Clara, CA, USA) at a power 
density of 50 mW/cm2 as measured with an optical power 
meter (PM 100, Thorlabs, Newton, NJ, USA). Cells were 
scratched 1 h after treatment. PI was then added to the 
cell suspension (final 2 µg/mL) and incubated at room 
temperature for 30 min, followed by flow cytometry. A 
488-nm argon ion laser was used for excitation. Signals 
from cells were collected with a 650 nm long-pass filter 
for PI.
Animal and tumor models
All in vivo procedures were conducted in compliance 
with the Guide for the Care and Use of Laboratory Animal 
Resources (1996), US National Research Council, and 
approved by the local Animal Care and Use Committee. 
Six to eight week old female homozygote athymic nude 
mice were purchased from Charles River (NCI-Frederick, 
Frederick, MD, USA). During the procedure, mice were 
anesthetized with inhaled 3–5% isoflurane and/or via 
intraperitoneal injection of 1 mg of sodium pentobarbital 
(Nembutal Sodium Solution, Ovation Pharmaceuticals 
Inc., Deerfield, IL, USA). In order to determine tumor 
volume, the greatest longitudinal diameter (length) and the 
greatest transverse diameter (width) were measured with 
an external caliper. Tumor volumes were based on caliper 
measurements and were calculated using the following 
formula; tumor volume = length × width2 × 0.5. Body 
weight was also measured. Mice were monitored daily 
for their general health. The presence of skin necrosis or 
toxicity attributable to the can225-IR700 was evaluated 
carefully noting skin color, general health, weight loss 
and loss of appetite. Tumor volumes were measured three 
times a week until the tumor volume reached 2000 mm3, 
whereupon the mice were euthanized with inhalation of 
carbon dioxide gas.
In vivo fluorescence imaging studies
TCC SH cells (2 × 106) were injected subcutaneously 
in the right dorsum of the mice. Tumors were studied after 
they reached volumes of approximately 50 mm3. Serial 
ventral and dorsal fluorescence images of IR700 were 
obtained with a Pearl Imager using a 700 nm fluorescence 
channel before and 0, ½, 1, 2, 3, 4, 5, 6, 9, 12, 24, 48, 
72, 96, 120, 144, and 168 hours after i.v. injection of 100 
µg of can225-IR700 via the tail vein. Pearl Cam Software 
(LICOR Biosciences, Lincoln, NE, USA) was used for 
analyzing fluorescence intensities. Regions of interests 
(ROIs) were placed on the tumor and liver to quantify 
Oncotarget19035www.oncotarget.com
the fluorescence intensities. ROIs were also placed in the 
adjacent non-tumor region as background (left dorsum and 
lower abdomen). Average fluorescence intensity of each 
ROI was calculated. Target-to-background ratios (TBR = 
fluorescence intensities of target / fluorescence intensities 
of background) were also calculated (n = 10).
Histological analysis
To detect the antigen-specific micro-distribution 
in the tumor, fluorescence microscopy was performed. 
Tumor xenografts were excised from mice without 
treatment (control), 24 h after injection of can225-IR700 
(APC i.v. only), 24 h after NIR exposure without can225-
IR700 (NIR light only) and 24 h after NIR-PIT (NIR-PIT). 
Fluorescence images, as well as white light images, of 
extracted tumors were obtained using a Pearl Imager with a 
700 nm fluorescence channel. Then, extracted tumors were 
frozen with optimal cutting temperature (OCT) compound 
(SAKURA Finetek Japan Co., Tokyo, Japan) and frozen 
sections (10 µm thick) were prepared. Fluorescence 
microscopy was performed using the BX61 microscope 
with the following filters: excitation wavelength 590 to 
650 nm, emission wavelength 665 to 740 nm long pass 
for IR700 fluorescence. DIC images were also acquired. 
To evaluate histological changes, bright-field microscopy 
was also performed. Extracted tumors were fixed with 
10% formalin and serial 10 µm slice sections were fixed 
on a glass slide with H&E staining.
In vivo NIR-PIT
TCC SH cells (2 × 106) were injected subcutaneously 
in the right dorsum of each mouse. Tumors were studied 
after they reached volumes of approximately 50 mm3. To 
examine the therapeutic effect of in vivo NIR-PIT on TCC 
SH tumors, tumor-bearing mice were randomized into 4 
groups of at least 10 animals per group for the following 
treatments: (1) no treatment (control); (2) 100 µg of 
can225-IR700 i.v. only, no NIR light exposure (APC i.v. 
only); (3) NIR light exposure only, NIR light exposure was 
administered at 50 J/cm2 on day 1 and 100 J/cm2 on day 2 
without can225-IR700 i.v. (NIR light only); (4) 100 µg of 
can225-IR700 i.v., NIR light exposure was administered 
at 50 J/cm2 on day 1 and 100 J/cm2 on day 2 after injection 
(NIR-PIT). Serial fluorescence images, as well as white 
light images, were obtained using a Pearl Imager with a 
700 nm fluorescence channel.
Statistical analysis
Data are expressed as means ± standard error of 
mean (SEM) from a minimum of five experiments, unless 
otherwise indicated. Statistical analyses were carried out 
using GraphPad Prism version 7 (GraphPad Software, La 
Jolla, CA, USA). For multiple comparisons, a one-way 
analysis of variance (ANOVA) followed by the Tukey’s 
correction for multiple comparisons was used. The 
cumulative probability of survival based on volume (2000 
mm3) were estimated in each group with a Kaplan–Meier 
survival curve analysis, and the results were compared 
with use of the log-rank test. Student’s t test was used 
to compare the treatment effects with that of control. A 
p-value of < 0.05 was considered statistically significant.
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